Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.54 |
| ▸ | IKBKB | O14920 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | CFTR | P13569 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166147 | 0.78 | MAPK8 (0.60) | — | |
| SCHEMBL163352 | 0.76 | KCNMA1 (0.45) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL16263805 | 0.76 | CFTR (0.55) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL167175 | 0.75 | GRIK1 (0.44) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL165620 | 0.73 | MAPK14 (0.51) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL11921318 | 0.73 | IKBKB (0.59) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL159515 | 0.72 | AGTR1 (0.50) | MEN1KMT2AALDH1A1 | |
| SCHEMBL16261522 | 0.72 | ALDH1A1 (0.60) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL5455703 | 0.71 | SMN1; SMN2 (0.49) | JAK2IKBKBMEN1EIF2AK2KMT2A | |
| SCHEMBL5898645 | 0.71 | IKBKB (0.80) | JAK2IKBKBMEN1EIF2AK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2611812-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030894-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317045-A1 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, TYK2 | JAK2 1/4885IKBKB 668/4885MEN1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.